MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

Search

Altimmune Inc

Abierto

4.15 -1.19

Resumen

Variación precio

24h

Actual

Mínimo

4.06

Máximo

4.23

Métricas clave

By Trading Economics

Ingresos

3.6M

-20M

Ventas

5K

Margen de beneficio

-391,500

Empleados

59

EBITDA

2.9M

-20M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+351.91% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-117M

346M

Apertura anterior

5.34

Cierre anterior

4.15

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Altimmune Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 jul 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 jul 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 jul 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 jul 2025, 22:38 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 jul 2025, 23:44 UTC

Charlas de Mercado

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Fall as Yen Strengthens -- Market Talk

16 jul 2025, 23:24 UTC

Charlas de Mercado

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 jul 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 jul 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Santos Cuts Top End of 2025 Production Guidance

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Production Recovery Underway in Cooper Basin

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 jul 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 jul 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 jul 2025, 23:13 UTC

Adquisiciones, fusiones, absorciones

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 jul 2025, 23:13 UTC

Adquisiciones, fusiones, absorciones

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 jul 2025, 23:12 UTC

Adquisiciones, fusiones, absorciones

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 jul 2025, 23:12 UTC

Adquisiciones, fusiones, absorciones

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Free Cash Flow From Operations US$620 Million

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 jul 2025, 22:43 UTC

Charlas de Mercado

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 jul 2025, 22:35 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

16 jul 2025, 22:35 UTC

Charlas de Mercado
Ganancias

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 jul 2025, 22:33 UTC

Charlas de Mercado
Ganancias

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 jul 2025, 22:28 UTC

Charlas de Mercado
Ganancias

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 jul 2025, 22:22 UTC

Charlas de Mercado
Ganancias

Market Talk Roundup: Latest on U.S. Politics

16 jul 2025, 22:22 UTC

Charlas de Mercado
Ganancias

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Comparación entre iguales

Cambio de precio

Altimmune Inc Esperado

Precio Objetivo

By TipRanks

351.91% repunte

Estimación a 12 meses

Media 18.89 USD  351.91%

Máximo 28 USD

Mínimo 1 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Altimmune Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

8

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

5.365 / 6.0486Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.